Indeed, the homozygous CaSR mutations, present in these patients, have been associated with milder alterations in Ca2+i signalling than homozygous muta­tions leading to NSHPT (Hannan et al. 2010a). The gene discussed is CASR; the disease is neonatal severe primary hyperparathyroidism.